NFKB1 and myeloid sarcoma: Nevertheless, R-flurbiprofen likely combines multiple effects at molecular targets independently of prostaglandins, which are currently being evaluated as therapeutic targets in MS, such as the PPARs (Dunn et al, 2010; Lovett-Racke et al, 2004; Xu & Drew, 2007), NF-κB (Mc Guire et al, 2013; van Loo et al, 2006) and p38 MAPK (Kleinewietfeld et al, 2013).